Optiscan Imaging Ltd (ASX:OIL) Advances Robotic Surgery Collaboration with Mayo Clinic
Robotic Surgery Collaboration Progresses
Optiscan Imaging Ltd (ASX:OIL) has advanced its collaboration with the Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery. The project, initiated under a Know-How Agreement signed in mid-2024, has met all target deliverables at the 12-month anniversary.
Development Milestones
Optiscan and Mayo Clinic have co-developed accessories integrating the company’s imaging probe into robotic surgical systems. Their joint efforts focus on creating a system that enhances surgical precision and patient outcomes. The development plan remains on track, with the next phase set to begin at the Mayo Clinic Florida campus.
Executive Comments
Optiscan CEO and Managing Director, Dr Camile Farah, said: “We are thrilled with the outcomes delivered to date from our collaboration with the Mayo Clinic. Just twelve months on from Optiscan signing a Know-How Agreement with this prestigious US medical care organisation, both groups have materially progressed an imaging system for use in robotic surgery. Harnessing the core strengths of both groups, all target deliverables at the 12-month anniversary of the Agreement have been met.
“This collaboration clearly highlights the versatility of our imaging platform. It will set the stage for the platform’s application across a range of clinical settings, improving both surgical precision and patient care. Optiscan and the Mayo Clinic are now busy developing a structured development process, which will have multiple milestones to guide the design, testing, and validation of this imaging system.
“Mayo Clinic’s commitment to innovation aligns perfectly with Optiscan’s vision. The work we are doing together aims to enhance the standard of care in breast cancer surgery by integrating state-of-the-art imaging into the robotic surgical process, with potential to deliver better outcomes for patients while advancing the future of robotic-assisted surgical procedures.
“Our collaboration with the Mayo Clinic is just one part of Optiscan’s commitment to transforming healthcare through innovation. Over the months ahead, we look forward to providing further updates to the market on our collaboration plan with the Mayo Clinic as well as other news flow that will clearly demonstrate the progress being made in our stated plans to grow Optiscan’s suite of unique software and hardware-related MedTech products.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
